NEW YORK (GenomeWeb) – NanoString Technologies today announced that the European Society for Medical Oncology has added the PAM50 gene signature to its clinical practice guidelines as a prognostic and predictive tool to determine benefit from chemotherapy.

NanoString's Prosigna Breast Cancer Gene Signature Assay is based on the PAM50 gene signature and runs on the firm's nCounter Dx Analysis System. The guidelines acknowledge the test has achieved an evidence level of 1B for its prognostic value, meaning its value has been demonstrated in individual randomized controlled trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.